Pembrolizumab and lenvatinib for advanced vulvar cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of vulvar cancer that cannot be removed by surgery, or that has come back or spread.
- You must not have had previous treatment with immunotherapy (like pembrolizumab) or VEGF inhibitors (like lenvatinib).
- You must be able to swallow pills and have a stored tumor sample for testing.
- Your cancer must have at least one measurable tumor on scans.
- You must be in generally good health (able to care for yourself) and have adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether adding two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy)—to the standard chemoradiation and brachytherapy can improve outcomes for women with high-risk locally advanced cervical cancer. The goal is to see if this combination helps control the cancer better than usual treatment.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
Hear when a new Vulva Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.